119 related articles for article (PubMed ID: 38863318)
1. Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort.
Cetin T; Celik S; Sozen S; Ozen H; Akdogan B; Aslan G; Baltaci S; Suer E; Bayazit Y; Izol V; Muezzinoglu T; Gokalp F; Tinay I
Urol J; 2024 Jun; ():. PubMed ID: 38863318
[TBL] [Abstract][Full Text] [Related]
2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
3. Oncological outcomes of papillary
Cetin T; Celik S; Sozen S; Akdogan B; Izol V; Aslan G; Suer E; Bayazit Y; Karakoyunlu N; Ozen H; Baltaci S; Gokalp F; Tinay I
Arch Ital Urol Androl; 2023 May; 95(2):11218. PubMed ID: 37254924
[TBL] [Abstract][Full Text] [Related]
4. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
6. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
[TBL] [Abstract][Full Text] [Related]
7. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Histological Variants on Oncological Outcomes After Surgical Resection of a Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus: A Multi-institutional Study.
Fleury R; Bertail T; Bensalah K; Bernhard JC; Audenet F; Waeckel T; Parier B; Champy C; Olivier J; Doumerc N; Tricard T; Branger N; Bruyere F; Neuville P; Surlemont L; Alexandre Long J; Fontenil A; Vallee M; Roupret M; Boissier R; Jacques Patard J; Durand M; Ouzaid I; Rouget B; Durand X; Joncour C; Belas O; Denise Gomez F; Bigot P; Khene ZE;
Eur Urol Open Sci; 2024 Apr; 62():123-130. PubMed ID: 38496822
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
10. Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis.
Frees S; Kamal MM; Knoechlein L; Bell R; Ziesel C; Neisius A; Thomas C; Brenner W; Jäger W; Thüroff JW; Roos FC
Urology; 2016 Dec; 98():81-87. PubMed ID: 27262395
[TBL] [Abstract][Full Text] [Related]
11. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
12. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
[TBL] [Abstract][Full Text] [Related]
13. [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].
May M; Zigeuner R; Aziz A; Cindolo L; Gilfrich C; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Hoschke B; Dalpiaz O; Stoltze A; Fenske F; Fritsche HM; Chromecki T; Lebentrau S; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief CG; Brookman-May S; ;
Urologe A; 2014 Feb; 53(2):228-35. PubMed ID: 23836364
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
15. Imaging Mass Spectrometry Is an Accurate Tool in Differentiating Clear Cell Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma: A Proof-of-concept Study.
Lu HC; Patterson NH; Judd AM; Reyzer ML; Sehn JK
J Histochem Cytochem; 2020 Jun; 68(6):403-411. PubMed ID: 32466698
[TBL] [Abstract][Full Text] [Related]
16. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
17. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
Avulova S; Cheville JC; Lohse CM; Gupta S; Potretzke TA; Tsivian M; Thompson RH; Boorjian SA; Leibovich BC; Potretzke AM
Eur Urol; 2021 Feb; 79(2):225-231. PubMed ID: 33172723
[TBL] [Abstract][Full Text] [Related]
18. 2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Schmeusser BN; Patil DH; Nicaise EH; Armas-Phan M; Nabavizadeh R; Narayan VM; Joshi SS; Ogan K; Osunkoya AO; Bilen MA; Master VA
Cancer; 2024 Feb; 130(3):453-466. PubMed ID: 37803521
[TBL] [Abstract][Full Text] [Related]
19. Oncological Outcomes of Patients with Non-Clear Cell Renal Cell Cancers: Subtypes of Unclassified and Translocation Renal Cell Cancers.
Gokalp F; Celik S; Sozen TS; Ozen AH; Aslan G; Izol V; Baltaci S; Muezzinoglu T; Akdogan B; Suer E; Tinay I
Urol J; 2022 Dec; 20(1):29-33. PubMed ID: 35892147
[TBL] [Abstract][Full Text] [Related]
20. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
